BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals ( BMRN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, BioMarin Pharmaceuticals fell 52 cents (-1.1%) to $49.18 on light volume. Throughout the day, 961,982 shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in price between $49.14-$49.91 after having opened the day at $49.48 as compared to the previous trading day's close of $49.70. Other companies within the Drugs industry that declined today were: Hemispherx Biopharma ( HEB), down 44.1%, Galena Biopharma ( GALE), down 17%, Idera Pharmaceuticals ( IDRA), down 11.5%, and Cardiome Pharma Corporation ( CRME), down 11.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $6.12 billion and is part of the health care sector. Shares are up 43.7% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share.

On the positive front, Opexa Therapeutics ( OPXA), up 25%, Vanda Pharmaceuticals ( VNDA), up 18.6%, Aoxing Pharmaceutical Company ( AXN), up 14.8%, and MEI Pharma ( MEIP), up 14.6%, were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half